- 80+ clinical sites in Poland, Bulgaria, Germany, Romania, Serbia
- 100+ investigators in oncology
- Access to drug-naïve patients, fast recruitment
Breast Cancer
- phase III trial in 200 patients
Prostate Cancer
- phase II trial in 40 patients with bone metastasis
Pancreatic Cancer
- phase III trial in 350 patients
Bladder Cancer
- phase II in 100 patients with bone metastasis
Leukemia
- phase III trial in 120 patients
Lymphoma
- phase III trial in 150 patients
- phase II trial in 70 Non-Hodgkin´s Lymphoma patients
Myeloma
- PK trial in 100 patients
Solid Tumors
- phase III trial in 200 patients
- PK trial in 80 patients